Valneva
- Market cap
- 556.61M
- P/E (TTM)i
- -2.91
- P/Bi
- 6.13
- EPSi
- -1.52
- Div yieldi
- 0.00%
- 52W posi
- 15%
Anonymous reader poll. Unscientific, not investment advice.
About Valneva
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.
- Founded
- 2015
- CEO
- Mr. Thomas Lingelbach
- Employees
- 674
- Headquarters
- Saint-Herblain, GE, France
- Fiscal year end
- 12-31
- Website
- valneva.com
Company profile
- Exchange
- US
- Symbol
- VALN
- Market-cap rank
- #3677
- Listing date
- 2021-05-06
- Market cap
- 556.61M
- Float cap
- 502.93M
- Shares out
- 94.82M
- Float shares
- 85.68M
Sectors & themes
Quote time 2026-10-08 08:10:17 · For reference only, not investment advice and not tailored to your situation.